A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Gag DNA Vaccine Alone or With IL-15 DNA, Boosted With HIV-1 Gag DNA + IL-15 DNA or HIV-1 Gag DNA + IL-12 DNA, in Healthy, HIV-1 Uninfected Adult Participants
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Enrollment
- 120
- Locations
- 7
- Primary Endpoint
- Laboratory measures of safety, as assessed after each injection
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine, HIV-1 gag DNA, with and without an IL-15 DNA adjuvant (at escalating doses of 100, 500, and 1500 mcg). This study will also test the safety of and immune response to the HIV-1 gag DNA vaccine plus IL-15 DNA adjuvant given with or without 2 other adjuvant-containing booster vaccines.
Detailed Description
The HIV epidemic is a major global health challenge, causing tremendous human suffering and economic loss throughout the world. The need for a safe, effective, and affordable HIV preventive vaccine is critical. This 2-part study will determine the safety and immunogenicity of the experimental HIV vaccine HIV-1 gag DNA with or without IL-15 adjuvant, boosted with either the HIV-1 gag DNA and IL-15 adjuvant vaccine or the HIV-1 gag DNA and IL-12 adjuvant vaccine. There are two parts to this study. Part A will last 12 months. In Part A, 48 participants will be randomly assigned to 1 of 4 groups in sequential order (dose escalation). All participants will receive 3 vaccinations. Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine or placebo. Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant or a placebo. Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant or a placebo. Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant or a placebo. Vaccinations will be given at Months 0, 1, and 3. There will be 11 study visits in Part A. A physical exam, pregnancy prevention counseling, medication history, and adverse event reporting will occur at most visits. Urine and blood collection will occur at some visits. Participants will also be asked to complete questionnaires at certain visits. Part B will last 15 months. In Part B, 72 participants will be randomly assigned to 1 of 2 groups. All Part B participants will receive 5 vaccinations. Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA or placebo; the vaccinations will occur at Months 0, 1, 3, 6, and 9. Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9. There will be 13 study visits in Part B. A physical exam, pregnancy prevention counseling, medication history, and adverse event reporting will occur at most visits. Urine and blood collection will occur at some visits. Participants will also be asked to complete questionnaires at certain visits.
Investigators
Eligibility Criteria
Inclusion Criteria
- •HIV uninfected
- •Access to a participating HIV Vaccine Trials Unit (HVTU)
- •Willing to receive HIV test results
- •Willing and able to comply with all study requirements
- •In good general health
- •Willing to use acceptable methods of contraception for at least 21 days prior to study entry and until the last study visit. More information about this criterion can be found in the protocol.
- •Hepatitis B surface antigen negative
- •Anti-hepatitis C virus (anti-HCV) antibody negative or negative HCV PCR if anti-HCV antibody is positive
Exclusion Criteria
- •HIV vaccines in prior HIV vaccine trial
- •Immunosuppressive medications within 168 days prior to first vaccination
- •Blood products within 120 days prior to first vaccination
- •Immunoglobulin within 60 days prior to first vaccination
- •Live attenuated vaccines within 30 days prior to first vaccination
- •Investigational research agents within 30 days prior to first vaccination
- •Medically indicated subunit or killed vaccines within 14 days prior to first study vaccine administration, or allergy treatment with antigen injections within 30 days prior to first vaccination
- •Current tuberculosis (TB) prophylaxis or therapy
- •Clinically significant medical condition, physical exam findings, abnormal laboratory results, or past medical history with clinically significant implications for current health
- •Any medical, psychiatric, or social condition that, in the opinion of the investigator, may interfere with the study
Outcomes
Primary Outcomes
Laboratory measures of safety, as assessed after each injection
Time Frame: 12 months postinjection for Part A, and 15 months after the first injection in Part B
Local and systemic reactogenicity signs and symptoms, as assessed after each injection
Time Frame: 12 months postinjection for Part A, and 15 months after the first injection in Part B
Adverse and serious adverse experiences, as assessed after each injection
Time Frame: 12 months postinjection for Part A, and 15 months after the first injection in Part B
Secondary Outcomes
- HIV-specific cellular responses by IFN-gamma ELISpot(12 months postinjection for Part A, and 15 months after the first injection in Part B)
- Social impact variables(At the end of the study)
- HIV binding antibody by ELISA(12 months postinjection for Part A, and 15 months after the first injection in Part B)